Saint Joseph, MO (PRWEB) April 1, 2010
IMULAN BioTherapeutics’ new product leukoSTAT™, is the first veterinary nutritional product containing the Immune Selective Anti-Inflammatory Derivatives (ImSAID®). This new technology uses naturally occurring amino acid complexes which evolved to regulate leukocytes, the source of all inflammatory processes. These specific amino acid sequences in leukoSTAT™ have been shown in numerous published studies to attenuate the over activation of the immune system, the underlying cause of all acute and chronic inflammatory conditions. IMULAN intends to evaluate leukoSTAT in a variety of settings to better understand its broad applications in veterinary medicine.
IMULAN is now focusing on critical care applications for leukoSTAT™, an environment which often has limited options to support patients. The ImSAIDs® have been previously evaluated in a variety of in vivo critical care models, including sepsis (e.g. SIRS) and inflammation of the pancreas, lungs, intestines, nervous system, and joints. leukoSTAT™ comes in highly palatable, small, chewable tablets so that the animal can easily ingest the amino acid complex and immediately begin the process of rebalancing the immune system.
IMULAN holds the veterinary patent rights to the ImSAIDs® technology platform and will be identifying partners that want to use this technology for nutraceutical use.
Imulan develops immune regulating, naturally-occurring substance for veterinary medicine. Imulan’s primary focus is to combine peptide pharmacology with immunology to manage inflammatory, infectious and immune mediated diseases in companion and production animals. Please visit http://www.IMULAN.com to learn more.
ImSAIDs® and leukoSTAT™ are trademarks of IMULAN BioTherapeutics, LLC